Latest Manufacturing Processes News

AdAlta has secured A$2.5 million in a strategic placement to push its lead CAR-T therapy BZDS1901 through critical US FDA regulatory steps and establish Australian manufacturing, building on promising clinical responses in advanced mesothelioma.

Weebit Nano has reached a crucial 2026 target as two customers tape-out chip designs incorporating its ReRAM technology, with one already showing a working prototype. This progress marks a significant step towards mass production and commercialisation of its advanced memory solutions.

Cynata Therapeutics is on the cusp of releasing critical data from its Phase 2 aGvHD and Phase 3 osteoarthritis trials in Q2 2026, while managing a tight cash runway and preparing for a capital raising.

Firebird Metals has locked in a purpose-built industrial facility in Osborne Park, Perth, to house its pioneering Australian Demonstration Plant, the only fully integrated manganese concentrate-to-cathode active material facility outside China.

AdAlta has secured Australian manufacturing for its lead CAR-T therapy BZDS1901, which has shown rare complete tumour clearance in advanced mesothelioma patients. This move is a key step toward local clinical trials and boosts the therapy’s global commercial appeal.

1414 Degrees (ASX:14D) advances its SiNTL silicon anode technology, aiming to disrupt lithium-ion batteries in the rapidly expanding drone and UAV sector with higher capacity and faster charging.

Wide Open Agriculture appoints Craig Swan as CEO and pivots to a contract manufacturing model to improve economics and scale lupin protein production, while receiving a A$1.69 million R&D tax rebate.

AdAlta, Oribiotech, and Cell Therapies have inked a Memorandum of Understanding to deploy Oribiotech’s IRO automated cell therapy manufacturing platform in Australia and Asia Pacific, aiming to slash costs and boost production speed for CAR-T therapies.

Patrys has raised A$3.2 million through a share placement to fund its injectable quetiapine program’s Phase 1A clinical trial and FDA pre-IND preparations.

Mesoblast has acquired exclusive rights to a patented chimeric antigen receptor platform designed to enhance the targeting and potency of its mesenchymal stromal cell therapies, aiming to expand treatment options for inflammatory and autoimmune diseases.

Metal Powder Works has independently confirmed its DirectPowder™ CP Titanium Grade 2 feedstock meets stringent ASTM B384 structural standards via Laser Powder Bed Fusion, reinforcing its position in aerospace additive manufacturing.

Mesoblast Limited (ASX:MSB, Nasdaq:MESO) reported net sales of US$30.3 million for its FDA-approved cellular therapy Ryoncil in the March quarter, bringing total revenue since launch close to US$100 million. Strong sales in February and March offset January’s seasonal dip.